This report was first published by Endpoints News. To see the original version, click here
Innorna, a Chinese biotech largely based in Shenzhen, won FDA clearance to begin a Phase 1 study of an mRNA therapy for refractory gout, the company told Endpoints News in an exclusive interview.
If successful, it could have implications far beyond gout. The study could be a major test of whether mRNA therapies and the lipid nanoparticles used to deliver them can be made safe and effective enough for chronic use in a common condition.
您已阅读16%（527字），剩余84%（2776字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。